Table 1

Summary of RCT-level source data

AuthorReddy et al4Kuck et al2Kuck et al1Al-Khatib et al5Sapp et al3Di Biase et al6
Name of trialSMASH VTVTACHSMSCALYPSOVANISHVISTA
Sample size12811011127259118
Mean age676667646866
LVEF (%)31.834.031.22431.232.3
Proportion of patients with NYHA class III/IV20%NYHA IV excludedNYHA IV excluded14.8%23.6% NYHA III
NYHA IV excluded
34%
ControlAADAADAADAADAADClinical ablation
InterventionAblationAblationAblationAblationAblationSubstrate ablation
Length of follow-up (months)22242862812
Mortality11% (AAD) vs
9% (ablation)
7% (AAD) vs
10% (ablation)
19% (AAD) vs
17% (ablation)
14% (AAD) vs
15% (ablation)
28% (AAD) vs
27% (ablation)
15% (C-ablation) vs
9% (S-ablation)
Readmission (%)19% (AAD) vs
6% (ablation)
55% (AAD) vs
33% (ablation)
44% (AAD) vs
39% (ablation)
50% (AAD) vs
38% (ablation)
31% (AAD) vs
25% (ablation)
32% (C-ablation) vs
12% (S-ablation)
Quality of lifeAbsentSF-36 form at 12 and 24 monthsSF-36 form at 0 and 23 monthsAbsentSubstudy with SF-36 form, EQ-5D, HADS, ICDC at 0, 3, 6, 12 monthsAbsent
  • AAD, antiarrhythmic drug; EQ-5D, EuroQol-5 Dimension; HADS, Hospital Anxiety and Depression Scale; ICDC, ICD Patient Concerns questionnaire; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RCT, randomised clinical trial; SF-36, Short Form-36 questionnaire; SMS, Substrate Modification Study.